Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04268069 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

A Phase 2 study, sponsored by ORA.

Completed
Registry status
Phase 2
Development phase
160
Enrollment target

NCT04268069 is a Phase 2 study that has completed, run by ORA. The registered enrollment target is 160 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04268069, a Phase 2 study, has completed, sponsored by ORA.

COMPLETED
Registry status
Phase 2
Development phase
160 participants
Enrollment target

Study Summary

Evaluation of safety and efficacy of PL9643 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye.

Interventions

  • DRUG Placebo Ophthalmic Solution
  • DRUG PL9643 Ophthalmic Solution

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2020-02-14
Est. Completion 2020-10-05
Phase Phase 2

Sponsor

ORA

19 total trials

What the Registry Record Tells You About NCT04268069

The ClinicalTrials.gov registry entry for NCT04268069 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ORA, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo Ophthalmic Solution is the first listed.

NCT04268069 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04268069 about?

NCT04268069 is a clinical study titled "Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye". Evaluation of safety and efficacy of PL9643 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye.

What is the current status of trial NCT04268069?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2020-02-14. Estimated completion is 2020-10-05.

What interventions are being tested in trial NCT04268069?

The interventions under investigation include: Placebo Ophthalmic Solution (DRUG), PL9643 Ophthalmic Solution (DRUG).

Who is sponsoring clinical trial NCT04268069?

This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.